Patents by Inventor Fernando L. Rock

Fernando L. Rock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS
    Publication number: 20100266599
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Application
    Filed: March 2, 2010
    Publication date: October 21, 2010
    Inventors: GERARD T. HARDIMAN, FERNANDO L. ROCK, J. FERNANDO BAZAN, ROBERT A. KASTELEIN, STEPHEN W.K. HO, YONG-JUN LIU
  • Human DNAX toll-like receptor 4 proteins, related reagents and methods
    Patent number: 7670603
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: March 2, 2010
    Assignee: Schering Corporation
    Inventors: Gerard T. Hardiman, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein, Stephen W. K. Ho, Yong-Jun Liu
  • HUMAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS
    Publication number: 20080199477
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Application
    Filed: April 9, 2008
    Publication date: August 21, 2008
    Inventors: Gerard T. Hardiman, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein, Stephen W.K. Ho, Yong-Jun Liu
  • Human Receptor Proteins; Related Reagents and Methods
    Publication number: 20080194800
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Application
    Filed: April 9, 2008
    Publication date: August 14, 2008
    Inventors: Gerard T. Hardiman, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein, Stephen W.K. Ho, Yong-Jun Liu
  • Human receptor proteins; related reagents and methods
    Patent number: 7271248
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: September 18, 2007
    Assignee: Schering Corporation
    Inventors: Gerard T. Hardiman, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein, Stephen W. K. Ho, Yong-Jun Liu
  • Human receptor proteins; related reagents and methods
    Publication number: 20030032090
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Application
    Filed: September 10, 2001
    Publication date: February 13, 2003
    Applicant: Schering Corporation, a New Jersey Corporation
    Inventors: Gerard T. Hardiman, Fernando L. Rock, Bazan J. Fernando, Robert A. Kastelein, Stephen W.K. Ho, Yong-Jun Liu
  • Mutational variants of mammalian proteins
    Patent number: 6225446
    Abstract: Muteins, which are mutational variants of mammalian proteins. Particular positions of natural proteins are identified as critical in providing various different activities. Specific embodiments demonstrate properties of variations at these positions.
    Type: Grant
    Filed: December 5, 1996
    Date of Patent: May 1, 2001
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein